The quantum leap in the early and precise detection of diseases at the molecular level, where all diseases originate, presents medicine with new challenges. For the first time, organ damage or loss of organ function can be prevented.

However, this requires targeted therapy. Each person responds differently to a medication for various reasons. High blood pressure/hypertensionAccording to the comprehensive study by Stenström and colleagues, all medication groups would have to be tested by treating physicians over a period of months, and their effectiveness would have to be assessed. This is not only due to the time and constant documentation required, but also due to the incomparability of the respective stress or relaxation situations. No doctor has the time, and no healthcare system can afford these complex patient response tests.

The technology from mosaiques enables rapid and precise adjustment of patient therapy, not only for hypertension! Based on the individual proteome, existing molecular predispositions and health events are analyzed and predicted with unparalleled precision, and the patient's individual response to the therapy is mapped based on their current reactive proteome. 

Cardiovascular events, such as a Myocardial infarction and the resulting possible hospitalization, Heart failure or even the onset of death are predicted by the proteome at a time when the predicted course can be averted through individualized therapy (lifestyle changes and medication). Studies on thousands of patients have shown this.

mosaiques’ proteomic tests also enable the early detection of Bile duct cancer and thus the urgent need or exclusion of liver transplantation in cases of bile duct inflammation. Early proteomic therapy evaluation improves the current prognosis of invasive ERCP/imaging (50%) to over 95% and can also enable timely surgical removal of the carcinoma.

Also at Prostate cancer Proteomic analysis demonstrates significantly more accurate detection of aggressive carcinoma than the current clinical standard. Total prostatectomy has previously been performed after a Gleason score of 3+4, which the Protect study considers non-aggressive carcinoma. The proteomic approach, in its scientific proteomic evaluation, reaches the same conclusion as the Protect study. The difference: proteomic analysis can perform this diagnosis non-invasively and promptly at any time and provide a prognosis.

This knowledge of the proteome, stored in millions of data points in the proteome database, including all clinical data, makes it possible to significantly reduce the risk of, for example, a cardiovascular event or incorrect treatment decisions. The database is fed only with data from qualified, published studies from cutting-edge medicine. The information thus obtained enables individualized therapy and dosage. Individualized precision medicine is based on the artificial intelligence algorithms developed by mosaiques tests, which have been and continue to be scientifically proven in over 100 evidence-based studies.